Published online before print February 11, 2008, doi: 10.1161/CIRCULATIONAHA.107.731794
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Circulation. 2008;117:1138-1144.)
© 2008 American Heart Association, Inc.
Epidemiology |
Association of Leukocyte Telomere Length With Circulating Biomarkers of the Renin-Angiotensin-Aldosterone System
The Framingham Heart Study
From the Framingham Heart Study of the National Heart, Lung, and Blood Institute, Framingham, Mass (R.S.V., S.D., L.A.C., E.J.B.); Evans Department of Medicine and Whitaker Cardiovascular Institute, Boston University School of Medicine, Boston, Mass (R.S.V., E.J.B.); Department of Biostatistics (S.D., L.A.C., C.W.) and Department of Epidemiology (L.A.C., E.J.B.), Boston University School of Public Health, Boston, Mass; Center for Cardiovascular Disease Prevention, Brigham and Women’s Hospital, Harvard Medical School, Boston, Mass (N.R.); Division of Cardiology, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston (T.J.W.); National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Md (D.L.); and Center of Human Development and Aging, University of Medicine and Dentistry of New Jersey, Newark (M.K., J.P.G., X.C., A.A.).
Correspondence to Ramachandran S. Vasan, MD, Framingham Heart Study, 73 Mt Wayte Ave, Suite 2, Framingham, MA 01702–5827. E-mail vasan{at}bu.edu
Received August 2, 2007; accepted November 30, 2007.
 |
Abstract |
|---|
 Top Abstract IntroductionMethodsResultsDiscussionReferences |
|---|
Background— Leukocyte telomere length (LTL) chronicles the cumulative burden of oxidative stress and inflammation over a life course. Activation of the renin-angiotensin-aldosterone system is associated with increased oxidative stress and inflammation. Therefore, LTL may be related to circulating biomarkers of the renin-angiotensin-aldosterone system.
Methods and Results— We evaluated the cross-sectional relations of LTL (dependent variable) to circulating renin and aldosterone concentrations and the renin-to-aldosterone ratio (all logarithmically transformed; independent variables) in 1203 Framingham Study participants (mean age, 59 years; 51% women). We used multivariable linear regression and adjusted for age, blood pressure, hypertension treatment, smoking, diabetes mellitus, body mass index, hormone replacement therapy, serum creatinine, and the urine sodium-to-creatinine ratio. Overall, multivariable-adjusted LTL was inversely related to renin (β coefficient per unit increase, –0.038; P=0.036), directly related to aldosterone (β=0.099; P=0.002), and inversely related to the renin-to-aldosterone ratio (β=–0.049; P=0.003). Relations of LTL to biomarkers were stronger in those with hypertension, although a formal test of interaction was not statistically significant (P=0.20). Individuals with hypertension displayed significant associations of LTL with renin (β=–0.060; P=0.005), aldosterone (β=0.134; P=0.002), and renin-to-aldosterone ratio (β=–0.072; P<0.001). Participants with hypertension who were in the top tertile of the renin-to-aldosterone ratio had LTL that was 182 base pairs shorter relative to those in the lowest tertile.
Conclusions— In our community-based sample, LTL was shorter in individuals with a higher renin-to-aldosterone ratio, especially in participants with hypertension. Additional investigations are warranted to confirm our observations.
Key Words: aldosterone • epidemiology • hypertension • oxidative stress • renin • telomere
|
Introduction |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Telomeres are tandem repeats of TTAGGG at the ends of chromosomes that preserve genomic integrity and progressively shorten with replication of cultured somatic cells.1 Telomeres demonstrate age-dependent shortening in proliferative somatic cells in vivo.2 Therefore, at any age, leukocyte telomere length (LTL) represents the balance between LTL at birth and the attrition that occurs thereafter. In clinical studies, shorter age-adjusted LTL has been associated with metabolic (oxidative stress, inflammation),3–6 structural (atherosclerosis and arterial stiffness),7–10 and environmental (cigarette smoking and obesity)11,12 indices of cardiovascular disease.
Clinical Perspective p 1144
Telomere length is a record of the replicative history of somatic cells13 because telomere repeats are lost with each cell division; such a loss is heightened with oxidative stress.14,15 These features might render LTL a valuable index of metabolic factors predisposing to atherosclerosis. First, inflammation, which enhances the turnover rate of leukocytes, increases the pace of LTL shortening. Second, as oxidative stress increases the rate of telomere attrition per cell division, it also accelerates LTL shortening. Accordingly, LTL chronicles the cumulative burden of inflammation and oxidative stress over the lifetime of an individual. Both inflammation and oxidative stress are major determinants in atherosclerosis, a process that is contingent on the continued recruitment of leukocytes16 and increased oxidative stress at the interface of the endothelium with blood.17 Such a process usually takes place over the course of many years, and it would be expressed by a higher pace of LTL attrition and shorter LTL.
On a parallel note, substantial data implicate increased activation of components of the renin-angiotensin-aldosterone system (RAAS) in the atherosclerotic process. The 2 major components of the RAAS are its primarily vasoactive arm, the renin-angiotensin system (RAS), and its primarily sodium-regulating arm, aldosterone, both of which evoke oxidative stress and inflammatory responses.18–21 We do not know, however, which of these 2 arms of the RAAS provokes comparatively more inflammation/oxidative stress in vivo and therefore might increase atherosclerotic risk more relative to the other. Given that LTL attrition chronicles the cumulative burden of inflammation/oxidative stress and is associated (inversely) with atherosclerosis,7,9,10 our objective was to relate LTL to circulating renin and aldosterone concentrations in a community-based sample to obtain insights into the issues noted above.
|
Methods |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Study Sample
In 1971, 5124 offspring (and their spouses) of the original Framingham Heart Study participants were enrolled in the Framingham Offspring Study.22 The sixth examination of this cohort occurred from 1995 to 1998 and was attended by 3532 individuals. In total, 1589 DNA samples from the sixth examination were available for LTL analysis. These subjects were selected to be biologically unrelated. Among the 1589 subjects, we excluded 386 individuals because of missing data on plasma renin or serum aldosterone (n=41) or inadequate quality or amount of DNA for LTL measurements (n=345). After these exclusions, 1203 individuals remained eligible for the present investigation. Participants included in the present investigation were not systematically different from the sample of eligible attendees who were not included (Appendix Table I in the online Data Supplement). The study protocol was approved by the Institutional Review Board at Boston University Medical Center, and all participants provided written informed consent.
Clinical Evaluation
At the sixth examination cycle (referred to as the index examination), all attendees underwent standardized evaluations, including medical history and physical examination, anthropometry, and laboratory assessment of cardiovascular risk factors. Hypertension was defined as systolic blood pressure 
140 mm Hg, diastolic blood pressure 90 mm Hg, or use of antihypertensive medications.23 Diabetes mellitus was defined as fasting glucose 126 mg/dL or use of insulin or hypoglycemic medications.24 Participants were considered current cigarette smokers if they reported having smoked cigarettes regularly during the previous year.
Measurement of Renin, Aldosterone, and Urinary Sodium
At the index examination, venous blood was drawn from fasting study participants, typically between 8 AM and 9 AM, with the participants in a recumbent position for 
5 to 10 minutes before the phlebotomy; participants were ambulatory before the blood draw. Blood specimens were centrifuged immediately, and serum/plasma was stored at –80°C without repeat freeze-thaw cycles until their assay in 2002.
Serum aldosterone concentration was measured from extracted and fractionated serum with a highly sensitive and specific radioimmunoassay (Quest Diagnostics, Cambridge, Mass) with a sensitivity of <1 ng/dL.25 The intra-assay coefficient of variation (CV) ranges from 3.8% (for high concentrations) to 6% (low concentrations) with corresponding interassay CVs varying from 4.0% to 9.8%. Plasma renin concentration was measured with a highly sensitive and specific immunochemiluminometric assay (Nichols Advantage Direct Renin Assay, Quest Diagnostics).26 The intra-assay CV ranges from 3.7% (at high levels) to 7.2% (at low levels), with the corresponding interassay CV ranging from 4.9% to 10%. This direct renin assay yields measurements that have a high degree of correlation with the plasma renin activity.27,28 Serum high-sensitivity C-reactive protein was measured with a Dade Behring BN100 nephelometer (Dade Behring Inc, Newark, Del) with an intra-assay CV of 2.2%.
Spot urine samples (3 mL) were collected at the index examination at the time of phlebotomy, temporarily stored at –4°C for up to 4 hours, and maintained at –20°C until analysis. Urine samples were thawed at room temperature, and urine sodium was measured with an automated ion-electrode method. Samples were analyzed in duplicate with an average intra-assay CV of 0.8%. Urinary creatinine concentration was determined by use of a modified Jaffe method with an average intra-assay CV of 1.7% to 3.8%. Urinary sodium excretion was expressed as millimoles of sodium per gram of urinary creatinine (referred to as urine sodium index).29
LTL Measurements
We performed Southern blot analyses and obtained the mean of the terminal restriction fragment lengths in DNA extracted from leukocytes. We refer to this mean as the LTL. Details of the method to measure LTL, including an illustrative figure (Appendix Figure I), are presented in the online Appendix. The CV for this approach (for samples measured in duplicate or triplicate on different gels and occasions and by 2 researchers) was 2.4%.
Statistical Analyses
We used multivariable linear regression models to relate serum aldosterone and plasma renin (independent variables modeled jointly) to LTL (dependent variable). Serum aldosterone and plasma renin concentrations were treated as continuous variables (natural logarithmic–transformed values because of a positively skewed distribution). We also related LTL to the ratio of the 2 biomarkers and present the results for the renin-to-aldosterone ratio (as opposed to the more conventionally used aldosterone-to-renin ratio) for ease of interpretation (see Results). The renin-to-aldosterone ratio was modeled as a continuous ratio and as tertiles. Because no evidence was found of effect modification of the relations of serum aldosterone and plasma renin and LTL by sex, all analyses were sex pooled, with sex incorporated as a covariate.
Two sets of models were constructed, a model that adjusted for age and sex alone and multivariable models that additionally adjusted for covariates known to influence LTL3,4,6,11,12 and plasma renin and aldosterone concentrations30,31: age, sex, systolic and diastolic blood pressures, hypertension treatment, current smoking status, diabetes mellitus, serum creatinine, urine sodium index, body mass index, and hormone replacement therapy. We tested for effect modification by age and hypertension status by incorporating corresponding interaction terms in multivariable models.
Because any association of biomarkers of the RAAS with LTL may be mediated by their proinflammatory effects, we performed secondary analyses adjusting for C-reactive protein in the multivariable models, in addition to the covariates listed above. Antihypertensive agents differentially affect plasma renin and aldosterone concentrations: Diuretics raise aldosterone and renin levels; angiotensin-converting enzyme inhibitors raise renin levels but lower aldosterone levels; β-blockers inhibit renin; and calcium channel blockers are generally neutral. Therefore, we conducted exploratory analyses to assess whether the association of LTL with biomarkers varied among treated and untreated participants with hypertension by incorporating appropriate interaction terms for use of antihypertensive medications in a model that evaluated the subgroup of participants with hypertension.
The authors had full access to and take full responsibility for the integrity of the data. All authors have read and agree to the manuscript as written.
|
Results |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
General Characteristics
The characteristics of our study sample (mean age, 59 years; 51% women) are displayed in Table 1. More than 40% of men and women in our sample had hypertension; Appendix Table II in the online-only Data Supplement details the use of antihypertensive medications in these individuals by drug class. The mean values and overall distribution of serum aldosterone were similar in men and women, whereas plasma renin levels were slightly higher in men, consistent with our prior reports on a larger sample.30,31
|
Serum aldosterone and plasma renin were positively correlated (age- and sex-adjusted Spearman r=0.21, P<0.001). The rate of LTL attrition with age for the entire cohort was 22±1.7 base pairs (bp) per year (r=–0.35, P<0.001). Age-adjusted LTL was longer in women than men (by 124 bp; men, 6.90±0.02 kilobases (kb); women, 7.02±0.02 kb; P<0.001) and in "never smokers" than current smokers (never smokers, 7.0158±0.03 kb; current smokers, 6.84±0.04 kb; P=0.0012). Body mass index was related inversely to LTL (decrease of 11±3 bp per unit increase; P<0.001).
Associations Between LTL and Aldosterone, Renin, and Renin-to-Aldosterone Ratio
Table 2 displays the results of regression analyses relating aldosterone, renin, and the renin-to-aldosterone ratio to LTL in the whole sample and stratified by hypertension status. Modeled together, after adjustment for covariates, LTL was inversely related to renin (P=0.036) and directly related to aldosterone (P=0.002). Results were similar when renin and aldosterone were modeled individually (online-only Data Supplement Appendix Table III). LTL was inversely related to the renin-to-aldosterone ratio (P=0.003).
|
We did not observe effect modification by hypertension status (P=0.20 for interaction). Nevertheless, we stratified all analyses by hypertension status (Table 2), given the limited power to detect significant interactions and the fundamental role of the RAS in hypertension. In these analyses, we observed in participants with hypertension statistically significant relations of LTL with renin (inverse; P=0.005), aldosterone (positive; P=0.002), and renin-to-aldosterone ratio (inverse; P<0.001). Relations of LTL to RAAS biomarkers were not statistically significant in nonhypertensive individuals. It is noteworthy that we had adequate statistical power to detect associations of a similar magnitude in the subsets without and with hypertension; we had 80% power to detect partial correlations of the biomarkers with LTL of 0.107 (R2=1.1%) and 0.124 (R2=1.54%), respectively, in the 2 groups.
The Figure displays the adjusted least-squares mean LTL according to tertiles of the renin-to-aldosterone ratio in the overall sample and in nonhypertensive and hypertensive participants. In the overall sample, individuals in the top tertile of the ratio had an LTL that was 108 bp shorter relative to those in the lowest tertile. Corresponding differences among nonhypertensive and hypertensive individuals (top compared with lowest tertile) were 59 and 182 bp, respectively.
|
Table 3 displays the results of analyses with additional adjustment for C-reactive protein. The associations seen in Table 2 remain robust after additional adjustment for C-reactive protein.
|
We performed secondary analyses focusing on the association of biomarkers with LTL in untreated (n=166) versus treated (n=347) participants with hypertension. No effect modification by antihypertensive medication use was observed (all P0.50 for interaction terms).
|
Discussion |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Principal Findings and Related Considerations
We observed that across a wide range of sodium intake (expressed in urinary sodium output) and after adjustment for sex, smoking, and blood pressure status, age-adjusted LTL correlated positively with plasma aldosterone and negatively with plasma renin. Thus, shortened age-adjusted LTL was expressed more frequently in individuals with the phenotype of a high renin-to-aldosterone ratio, ie, a more active RAS. In large measure, this association was driven by the individuals with hypertension. Both angiotensin II18,21 and aldosterone20,21 provoke inflammation/oxidative stress. One potential explanation for our finding may be that a preferential reliance on the RAS over aldosterone to maintain blood pressure could generate more inflammation/oxidative stress and pose greater atherosclerotic risk. This speculation is based on findings that shortened LTL ostensibly reflects an increased cumulative burden of inflammation/oxidative stress and is strongly associated with atherosclerosis.7,9,10
Individuals with higher plasma renin levels have been reported to have increased mortality risk, thereby implicating increased activity of the RAS in disease states.32–35 The stronger associations we noted in hypertensive individuals are consistent with greater activation of the RAS in those with elevated blood pressure. Angiotensin II is a powerful activator of the p53/p21 pathways, which play a key role in cellular senescence.36 Indeed, shortened LTL has been observed in a host of aging-related diseases, particularly atherosclerotic cardiovascular disease,6,8–10,37 the common denominator for which is increased burden of oxidative stress and inflammation.
The positive association of LTL with aldosterone concentrations in our investigation conflicts with a recent report by Benetos et al,38 who observed that LTL was inversely correlated with plasma aldosterone in normotensive and mildly hypertensive men. That report was based on a small sample (n=75), and the investigators adjusted only for age (raising the issue of residual confounding). No measurements of plasma renin were available in that study.
We note that LTL is heritable11,39–42 and that shortened LTL is associated with a host of risk factors for cardiovascular disease and diminished lifespan, including male sex,6,11,43 insulin resistance,4,44 low socioeconomic status,45 cigarette smoking,11,12 and generally unhealthy lifestyle.43 The shorter LTL in smokers than nonsmokers is in line with the concept that the smoking-induced increased burden of oxidative stress and inflammation46–48 accelerates not only cardiovascular aging but also systemic aging.49
Postulated Mechanisms Underlying the Principal Findings
Considerable interaction was observed between angiotensin II and aldosterone, and the targets of both agents are diverse and not mutually exclusive.18–21 For instance, angiotensin II is a determinant in aldosterone release from the adrenal gland and has a major impact on renal sodium reabsorption in the proximal tubules, whereas the targets of aldosterone include the heart and vasculature. That said, we can still broadly divide the RAAS into its renin-angiotensin (RAS) arm and the aldosterone arm. For a given sodium intake, the relative dependency on aldosterone versus angiotensin II for maintaining blood pressure homeostasis might be an important determinant of the correlates of LTL. Our findings raise the possibility that a preponderance of angiotensin II activity (as reflected by renin levels) relative to aldosterone for the modulation of blood pressure (as evidenced by a high renin-to-aldosterone ratio) may promote an increased burden of inflammation and oxidative stress, expressed in a shorter LTL. This proposed paradigm may serve as a theoretical framework that integrates blood pressure regulation, sodium homeostasis, vascular tone, RAAS, and vascular aging, and it merits further study.
Study Strengths and Limitations
The strengths of this work include the community-based sample, the blinded assessments of LTL and biomarkers of the RAAS, and adjustment for multiple confounders in multivariable analyses. However, several limitations of our study should be noted. First, circulating biomarkers may not adequately reflect the degree of activation of the RAAS in tissues. Second, whereas LTL might be a record of the cumulative burden of oxidative stress and inflammation during the lifetime of the individual, the single measures of renin and aldosterone reflect the current status of the RAAS in ambulatory individuals. Additionally, we did not evaluate biomarkers of oxidative stress at the index examination. However, we have previously reported4 an inverse association of LTL and urinary excretion of isoprostanes (an index of systemic oxidative stress) measured at an examination 4 years after the examination at which LTL measurements were obtained. Finally, our sample comprised predominantly middle-aged to elderly whites of European descent. The generalizability of our findings to younger individuals or other ethnicities is unknown.
Conclusions
Our observations in a moderate-sized community-based sample indicate that individuals, primarily those with hypertension, with a higher renin-to-aldosterone ratio display shorter LTL. We hypothesize, on the basis of these observations, that a greater dependency on angiotensin II versus aldosterone to regulate blood pressure entails a relative increase in the cumulative burden of oxidative stress and inflammation and heightens the atherosclerotic risk. In this regard, a recent study showed that shortened LTL predicts coronary artery disease events.10 Both cross-sectional and longitudinal studies are warranted to confirm the link between LTL and the RAAS.
|
Acknowledgments |
|---|
Sources of Funding
This project was supported by National Institutes of Aging grants AG021593 and AG028321 and by National Heart, Lung, and Blood Institute contract NO1-HC 25195 and grants 2K24 HL 4334 and R01HL67288.
Disclosures
None.
|
References |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
1. Wong JM, Collins K. Telomere maintenance and disease. Lancet. 2003; 362: 983–988.[CrossRef][Medline] [Order article via Infotrieve]
2. Blackburn EH. Telomere states and cell fates. Nature. 2000; 408: 53–56.[CrossRef][Medline] [Order article via Infotrieve]
3. Aviv A, Valdes A, Gardner JP, Swaminathan R, Kimura M, Spector TD. Menopause modifies the association of leukocyte telomere length with insulin resistance and inflammation. J Clin Endocrinol Metab. 2006; 91: 635–640.
4. Demissie S, Levy D, Benjamin EJ, Cupples LA, Gardner JP, Herbert A, Kimura M, Larson MG, Meigs JB, Keaney JF, Aviv A. Insulin resistance, oxidative stress, hypertension, and leukocyte telomere length in men from the Framingham Heart Study. Aging Cell. 2006; 5: 325–330.[CrossRef][Medline] [Order article via Infotrieve]
5. Epel ES, Blackburn EH, Lin J, Dhabhar FS, Adler NE, Morrow JD, Cawthon RM. From the cover: accelerated telomere shortening in response to life stress. Proc Natl Acad Sci U S A. 2004; 101: 17312–17315.
6. Fitzpatrick AL, Kronmal RA, Gardner JP, Psaty BM, Jenny NS, Tracy RP, Walston J, Kimura M, Aviv A. Leukocyte telomere length and cardiovascular disease in the Cardiovascular Health Study. Am J Epidemiol. 2007; 165: 14–21.
7. Benetos A, Okuda K, Lajemi M, Kimura M, Thomas F, Skurnick J, Labat C, Bean K, Aviv A. Telomere length as an indicator of biological aging: the gender effect and relation with pulse pressure and pulse wave velocity. Hypertension. 2001; 37: 381–385.
8. Benetos A, Gardner JP, Zureik M, Labat C, Xiaobin L, Adamopoulos C, Temmar M, Bean KE, Thomas F, Aviv A. Short telomeres are associated with increased carotid atherosclerosis in hypertensive subjects. Hypertension. 2004; 43: 182–185.
9. Brouilette S, Singh RK, Thompson JR, Goodall AH, Samani NJ. White cell telomere length and risk of premature myocardial infarction. Arterioscler Thromb Vasc Biol. 2003; 23: 842–846.
10. Brouilette SW, Moore JS, McMahon AD, Thompson JR, Ford I, Shepherd J, Packard CJ, Samani NJ. Telomere length, risk of coronary heart disease, and statin treatment in the West of Scotland Primary Prevention Study: a nested case-control study. Lancet. 2007; 369: 107–114.[CrossRef][Medline] [Order article via Infotrieve]
11. Nawrot TS, Staessen JA, Gardner JP, Aviv PA. Telomere length and possible link to X chromosome. Lancet. 2004; 363: 507–510.[CrossRef][Medline] [Order article via Infotrieve]
12. Valdes AM, Andrew T, Gardner JP, Kimura M, Oelsner E, Cherkas LF, Aviv A, Spector TD. Obesity, cigarette smoking, and telomere length in women. Lancet. 2005; 366: 662–664.[CrossRef][Medline] [Order article via Infotrieve]
13. Stewart SA, Weinberg RA. Telomeres: cancer to human aging. Annu Rev Cell Dev Biol. 2006; 22: 531–557.[CrossRef][Medline] [Order article via Infotrieve]
14. Hall DB, Holmlin RE, Barton JK. Oxidative DNA damage through long-range electron transfer. Nature. 1996; 382: 731–735.[CrossRef][Medline] [Order article via Infotrieve]
15. von Zglinicki T. Role of oxidative stress in telomere length regulation and replicative senescence. Ann N Y Acad Sci. 2000; 908: 99–110.[Medline] [Order article via Infotrieve]
16. Hansson GK, Libby P. The immune response in atherosclerosis: a double-edged sword. Nat Rev Immunol. 2006; 6: 508–519.[CrossRef][Medline] [Order article via Infotrieve]
17. Gutierrez J, Ballinger SW, rley-Usmar VM, Landar A. Free radicals, mitochondria, and oxidized lipids: the emerging role in signal transduction in vascular cells. Circ Res. 2006; 99: 924–932.
18. Brasier AR, Recinos A III, Eledrisi MS. Vascular inflammation and the renin-angiotensin system. Arterioscler Thromb Vasc Biol. 2002; 22: 1257–1266.
19. Fiebeler A, Luft FC. The mineralocorticoid receptor and oxidative stress. Heart Fail Rev. 2005; 10: 47–52.[CrossRef][Medline] [Order article via Infotrieve]
20. Funder JW. Aldosterone, mineralocorticoid receptors and vascular inflammation. Mol Cell Endocrinol. 2004; 217: 263–269.[CrossRef][Medline] [Order article via Infotrieve]
21. Mehta PK, Griendling KK. Angiotensin II cell signaling: physiological and pathological effects in the cardiovascular system. Am J Physiol Cell Physiol. 2007; 292: C82–C97.
22. Kannel WB, Feinleib M, McNamara PM, Garrison RJ, Castelli WP. An investigation of coronary heart disease in families: the Framingham Offspring Study. Am J Epidemiol. 1979; 110: 281–290.
23. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, Jones DW, Materson BJ, Oparil S, Wright JT Jr, Roccella EJ. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 Report. JAMA. 2003; 289: 2560–2572.
24. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care. 1997; 20: 1183–1197.[Medline] [Order article via Infotrieve]
25. Ito T, Woo J, Haning R, Horton R. A radioimmunoassay for aldosterone in human peripheral plasma including a comparison of alternate techniques. J Clin Endocrinol Metab. 1972; 34: 106–112.
26. de Bruin RA, Bouhuizen A, Diederich S, Perschel FH, Boomsma F, Deinum J. Validation of a new automated renin assay. Clin Chem. 2004; 50: 2111–2116.
27. Ferrari P, Shaw SG, Nicod J, Saner E, Nussberger J. Active renin versus plasma renin activity to define aldosterone-to-renin ratio for primary aldosteronism. J Hypertens. 2004; 22: 377–381.[CrossRef][Medline] [Order article via Infotrieve]
28. Perschel FH, Schemer R, Seiler L, Reincke M, Deinum J, Maser-Gluth C, Mechelhoff D, Tauber R, Diederich S. Rapid screening test for primary hyperaldosteronism: ratio of plasma aldosterone to renin concentration determined by fully automated chemiluminescence immunoassays. Clin Chem. 2004; 50: 1650–1655.
29. Flack JM, Grimm RH Jr, Staffileno BA, Dnsc, Elmer P, Yunis C, Hedquist L, Dudley A. New salt-sensitivity metrics: variability-adjusted blood pressure change and the urinary sodium-to-creatinine ratio. Ethn Dis. 2002; 12: 10–19.[Medline] [Order article via Infotrieve]
30. Kathiresan S, Larson MG, Benjamin EJ, Corey D, Murabito JM, Fox CS, Wilson PW, Rifai N, Meigs JB, Ricken G, Lifton RP, Levy D, Vasan RS. Clinical and genetic correlates of serum aldosterone in the community: the Framingham Heart Study. Am J Hypertens. 2005; 18: 657–665.[CrossRef][Medline] [Order article via Infotrieve]
31. Newton-Cheh C, Guo CY, Gona P, Larson MG, Benjamin EJ, Wang TJ, Kathiresan S, O’Donnell CJ, Musone SL, Camargo AL, Drake JA, Levy D, Hirschhorn JN, Vasan RS. Clinical and genetic correlates of aldosterone-to-renin ratio and relations to blood pressure in a community sample. Hypertension. 2007; 49: 846–856.
32. Alderman MH, Madhavan S, Ooi WL, Cohen H, Sealey JE, Laragh JH. Association of the renin-sodium profile with the risk of myocardial infarction in patients with hypertension. N Engl J Med. 1991; 324: 1098–1104.[Abstract]
33. Alderman MH, Ooi WL, Cohen H, Madhavan S, Sealey JE, Laragh JH. Plasma renin activity: a risk factor for myocardial infarction in hypertensive patients. Am J Hypertens. 1997; 10: 1–8.[Medline] [Order article via Infotrieve]
34. Brunner HR, Laragh JH, Baer L, Newton MA, Goodwin FT, Krakoff LR, Bard RH, Buhler FR. Essential hypertension: renin and aldosterone, heart attack and stroke. N Engl J Med. 1972; 286: 441–449.[Medline] [Order article via Infotrieve]
35. Wang TJ, Gona P, Larson MG, Tofler GH, Levy D, Newton-Cheh C, Jacques PF, Rifai N, Selhub J, Robins SJ, Benjamin EJ, D’Agostino RB, Vasan RS. Multiple biomarkers for the prediction of first major cardiovascular events and death. N Engl J Med. 2006; 355: 2631–2639.
36. Minamino T, Komuro I. Vascular cell senescence: contribution to atherosclerosis. Circ Res. 2007; 100: 15–26.
37. Cawthon RM, Smith KR, O’Brien E, Sivatchenko A, Kerber RA. Association between telomere length in blood and mortality in people aged 60 years or older. Lancet. 2003; 361: 393–395.[CrossRef][Medline] [Order article via Infotrieve]
38. Benetos A, Gardner JP, Kimura M, Labat C, Nzietchueng R, Dousset B, Zannad F, Lacolley P, Aviv A. Aldosterone and telomere length in white blood cells. J Gerontol A Biol Sci Med Sci. 2005; 60: 1593–1596.
39. Andrew T, Aviv A, Falchi M, Surdulescu GL, Gardner JP, Lu X, Kimura M, Kato BS, Valdes AM, Spector TD. Mapping genetic loci that determine leukocyte telomere length in a large sample of unselected female sibling pairs. Am J Hum Genet. 2006; 78: 480–486.[CrossRef][Medline] [Order article via Infotrieve]
40. Njajou OT, Cawthon RM, Damcott CM, Wu SH, Ott S, Garant MJ, Blackburn EH, Mitchell BD, Shuldiner AR, Hsueh WC. Telomere length is paternally inherited and is associated with parental lifespan. Proc Natl Acad Sci U S A. 2007; 104: 12135–12139.
41. Slagboom PE, Droog S, Boomsma DI. Genetic determination of telomere size in humans: a twin study of three age groups. Am J Hum Genet. 1994; 55: 876–882.[Medline] [Order article via Infotrieve]
42. Vasa-Nicotera M, Brouilette S, Mangino M, Thompson JR, Braund P, Clemitson JR, Mason A, Bodycote CL, Raleigh SM, Louis E, Samani NJ. Mapping of a major locus that determines telomere length in humans. Am J Hum Genet. 2005; 76: 147–151.[CrossRef][Medline] [Order article via Infotrieve]
43. Bekaert S, De Meyer T, Rietzschel ER, De Buyzere ML, De Bacquer D, Langlois M, Segers P, Cooman L, Van Damme P, Cassiman P, Van Criekinge W, Verdonck P, De Backer GG, Gillebert TC, Van Oostveldt P. Telomere length and cardiovascular risk factors in a middle-aged population free of overt cardiovascular disease. Aging Cell. 2007; 6: 639–647.[CrossRef][Medline] [Order article via Infotrieve]
44. Gardner JP, Li S, Srinivasan SR, Chen W, Kimura M, Lu X, Berenson GS, Aviv A. Rise in insulin resistance is associated with escalated telomere attrition. Circulation. 2005; 111: 2171–2177.
45. Cherkas LF, Aviv A, Valdes AM, Hunkin JL, Gardner JP, Surdulescu GL, Kimura M, Spector TD. The effects of social status on biological aging as measured by white-blood-cell telomere length. Aging Cell. 2006; 5: 361–365.[CrossRef][Medline] [Order article via Infotrieve]
46. Churg A. Interactions of exogenous or evoked agents and particles: the role of reactive oxygen species. Free Radic Biol Med. 2003; 34: 1230–1235.[CrossRef][Medline] [Order article via Infotrieve]
47. Repine J, Bast A, Lankhorst I. Oxidative stress in chronic obstructive pulmonary disease: Oxidative Stress Study Group. Am J Respir Crit Care Med. 1997; 156: 341–357.
48. van der Vaart H, Postma DS, Timens W, Ten Hacken NHT. Acute effects of cigarette smoke on inflammation and oxidative stress: a review. Thorax. 2004; 59: 713–721.
49. Bernhard D, Moser C, Backovic A, Wick G. Cigarette smoke: an aging accelerator? Exp Gerontol. 2007; 42: 160–165.[CrossRef][Medline] [Order article via Infotrieve]
|
Footnotes |
|---|
The online-only Data Supplement, consisting of an Appendix with tables and a figure, can be found with this article at http://circ.ahajournals.org/ cgi/content/full/CIRCULATIONAHA.107.731794/DC1.
Guest Editor for this article was Daniel W. Jones, MD.
Related Article:
Circulation 2008 117: 1121-1123.
This article has been cited by other articles:
 |
|
 |
|
  R. C. Kaplan, A. L. Fitzpatrick, M. N. Pollak, J. P. Gardner, N. S. Jenny, A. P. McGinn, L. H. Kuller, H. D. Strickler, M. Kimura, B. M. Psaty, et al. Insulin-Like Growth Factors and Leukocyte Telomere Length: The Cardiovascular Health Study J Gerontol A Biol Sci Med Sci, November 1, 2009; 64A(11): 1103 - 1106. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. S. Vasan, S. Demissie, M. Kimura, L. A. Cupples, C. White, J. P. Gardner, X. Cao, D. Levy, E. J. Benjamin, and A. Aviv Association of Leukocyte Telomere Length With Echocardiographic Left Ventricular Mass: The Framingham Heart Study Circulation, September 29, 2009; 120(13): 1195 - 1202. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Z. Yang, X. Huang, H. Jiang, Y. Zhang, H. Liu, C. Qin, G. M. Eisner, P. Jose, L. Rudolph, and Z. Ju Short Telomeres and Prognosis of Hypertension in a Chinese Population Hypertension, April 1, 2009; 53(4): 639 - 645. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Aviv, W. Chen, J. P. Gardner, M. Kimura, M. Brimacombe, X. Cao, S. R. Srinivasan, and G. S. Berenson Leukocyte Telomere Dynamics: Longitudinal Findings Among Young Adults in the Bogalusa Heart Study Am. J. Epidemiol., February 1, 2009; 169(3): 323 - 329. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. S.M. Wong, H. Oeseburg, R. A. de Boer, W. H. van Gilst, D. J. van Veldhuisen, and P. van der Harst Telomere biology in cardiovascular disease: the TERC-/- mouse as a model for heart failure and ageing Cardiovasc Res, February 1, 2009; 81(2): 244 - 252. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Huzen, D. J. van Veldhuisen, and P. van der Harst Letter by Huzen et al Regarding Article, "Association of Leukocyte Telomere Length With Circulating Biomarkers of the Renin-Angiotensin-Aldosterone System: The Framingham Heart Study" Circulation, November 4, 2008; 118(19): e688 - e688. [Full Text] [PDF]
|
|
|
|
|
|
R. S. Vasan, S. Demissie, L. A. Cupples, E. J. Benjamin, C. White, M. Kimura, J. P. Gardner, X. Cao, A. Aviv, N. Rifai, et al. Response to Letter Regarding Article, "Association of Leukocyte Telomere Length With Circulating Biomarkers of the Renin-Angiotensin-Aldosterone System: The Framingham Heart Study" Circulation, November 4, 2008; 118(19): e689 - e689. [Full Text] [PDF]
|
|
|
|
 |
|
 L. S.M. Wong, R. A. de Boer, N. J. Samani, D. J. van Veldhuisen, and P. van der Harst Telomere biology in heart failure Eur J Heart Fail, November 1, 2008; 10(11): 1049 - 1056. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||